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Background: This study was carried out to evaluate total basal bilirubin levels as a predictive
factor for survival and toxicity in patients with advanced colorectal carcinoma treated with
CTP-11-based regimens.
Patients and methods: The analysis was carried out on a data base including 287 patients
affected by advanced colorectal carcinoma all treated with CPT-11 plus bolus and continu-
ous venous infusion intravenous folinic acid and 5-fluorouracil on a biweekly schedule
(FOLFIRI regimen). Patients were divided into four groups according to basal bilirubin levels
as follows: <0.49 mg/dl; >0.50 and <0.99 mg/dl; >1.00 and <1.49 mg/dl; >1.50 mg/dl. Analysis
of overall median survival and time-to-progression were correlated to performance status
at entry, volume of liver metastases, and carcinoembrionary antigen.
Results: Global statistical analysis showed that bilirubin levels were strongly correlated
with time-to-progression and overall survival in a statistically significant fashion
(p < 0.0001). The size of liver metastases represents the only study parameter which is cor-
related to basal bilirubin levels in a statistically significant fashion. Neutropaenia and diar-
rhoea were also correlated to baseline bilirubin levels in a statistically significant manner
(p = 0.001).
Conclusions: Data reported in this study support the observation that basal bilirubin levels
are a biomarker able to predict, at least in part, the clinical efficacy and toxicity of CPT-11-
based chemotherapy in patients with advanced colorectal carcinoma.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
CPT-11 is a semi-synthetic analogue of camptothecin, a vege-
tal alkaloid derived from Camptotheca acuminata which inter-er Ltd. All rights reserved
; fax: +39 0916806906.
ebbia).feres with topoisomerase-I enzymatic system via a complex
metabolic pathway.1 CPT-11 is one of the chemotherapeutic
agents most frequently employed in the first- or second-line
treatment of advanced colorectal (aCRC),2,3 gastric4 and.
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istration, myelosuppression and delayed-type diarrhoea are
the most common – often unpredictable – side-effects seen
in patients treated with this topoisomerase-I inhibitor which
may be severe enough to represent a serious clinical con-
cern.1–5
The complex metabolism of irinotecan probably contrib-
utes to its toxicity variability. CPT-11 is eliminated mainly by
hepatic route and in a lesser degree by renal excretion. In
the liver CPT-11 is metabolised by a tissue carboxyesterase
to an active metabolite – i.e. SN-38 – which has an antineo-
plastic activity 100–1000 times more effective than the paren-
tal compound and into two inactive metabolites – called APC
and NPC – by CYP3A4 and CYP3A5 isoenzymes belonging to
the P450 cytochrome enzymatic system.1,6,7 SN-38 is detoxi-
fied in the liver to SN-38 glucuronide (SN-38-G) by microsomal
glucuronisation enzymes such as uridine-diphosphate glucu-
ronsyltransferase 1A1 isoform (UGT1A1), which is considered
the principal effector of the detoxification process8 UGT1A1
also catalyses the glucuronisation of bilirubin as demon-
strated by the altered bilirubin metabolism in patients af-
fected by the Gilbert’s syndrome, which is related to
UGT1A1 polymorphism. These patients may develop life-
threatening toxicity after CPT-11 administration both as grade
4 diarrhoea and neutropaenia.9 Patients with this genetic
modification have a SN-38 glucuronisation activity much low-
er than that observed in normal individuals.
Delayed-type diarrhoea, defined as diarrhoea occurring
more than 24 h after administration of irinotecan, is probably
directly mediated by high concentrations of intraluminal
SN-38, which is formed partly out of SN-38G by bacterial
b-glucuronidases.10 Severe delayed-type diarrhoea has been
reported to occur in up to 30–40% of patients and necessitates
hospitalisation for intravenous re-hydration in about 10%
of patients and may be a life-threatening or even fatal
event.1–5 Apart from morbidity, this type of diarrhoea results
in expanded health-care costs, and even mild diarrhoea
may influence continuation of an otherwise active treatment.
Therefore there is need for clinical and biological predictive
factors able to identify patients at risk for acute and life-
threatening side-effects in order to ameliorate treatment
efficacy and safety.
Several investigators have addressed the potential rela-
tionships between patients clinical characteristics to efficacy
and toxicity of CPT-11 in aCRC.11,12 The aim of this study was
to explore the possible relationship between patients’ clinical
characteristics, basal bilirubin levels and survival.
2. Patients and methods
2.1. Study design and patients selection
This secondary analysis was carried out in a series of 287 pa-
tients treated during three consecutive controlled trials of
the GOIM which have been published recently.13–16 All pa-
tients were chemonaive and required to have biopsy-proven
histologically confirmed aCRC. The other eligibility criteria
included the following: bi-dimensionally measurable dis-
ease, age between 18 and 75 years, life expectancy of at least
3 months, performance status (PS) 0–2 according to theECOG scale, adequate bone marrow (platelets count
P100.000/mm3, WBC count >4000/mm3, granulocyte count
of P1500/mm3, a haemoglobin level of P10.0 g/mm3), renal
(serum creatinine concentration 62.0 mg/dl), and hepatic
functions (serum bilirubin level 62.0 mg/dl and AST three
or less times the normal level in the absence of liver involve-
ment with cancer or up to five times the institutional nor-
mal level when cancer was present in the liver). No
concurrent uncontrolled medical illness was allowed. Pa-
tients had to be previously untreated for advanced disease,
but prior adjuvant chemotherapy was allowed if P6 months
had relapsed since discontinuation of treatment. Patients
were excluded if these criteria were not met and also in
the presence of active infections, cerebral metastases, evi-
dence of congestive heart failure, serious cardiac arrhyth-
mias, symptoms of coronary artery disease, history of
thromboembolic disease or other malignancy (apart from
adequately treated non-melanotic skin cancer and carci-
noma in situ of the uterine cervix), or any psychological con-
dition that precluded treatment or adequate follow-up.
Radiotherapy was allowed only in sites other than those
measurable for response evaluation. Patients had to agree
to, and sign, a statement of informed consent prior to entry
in this study. Informed consent was previously approved by
the Scientific Committee of the GOIM and ethics committees
of each individual institution.2.2. Chemotherapy schedule
All patients included into the analysis had been treated with
the FOLFIRI regimen: CPT-11 180 mg/m2 on day 1 with LV5FU2
regimen: leucovorin (LV) at 100 mg/m2 administered as a 2-h
infusion before 5FU at 400 mg/m2 as an i.v. bolus, and 5FU
at 600 mg/m2 as a 22-h infusion immediately after 5FU bolus
injection on day 1 and 2. The treatment was repeated every 2
weeks. Globally considered these series of patients achieved
an overall response rate of 34.5% (95% confidence interval
[CI]: 29–40%) with a median time-to-progression, median
duration of response, and survival of 7 months, 10.5 months,
and 14 months, respectively.2.3. Statistics
Baseline serum levels were determined by the participating
institution’s laboratory. As previously described,11 patients
were divided into four groups according to basal bilirubin lev-
els recorded just before the first cycle of chemotherapy: group
1 < 0.49 mg/dl, group 2 > 0, 50e < 0.99 mg/dl, group 3 > 1.00e <
1.49 mg/dl, and group 4 > 1.50 mg/dl. No enrolled patient had
bilirubin >2 mg/dl. Analysis of time-to-progression (TTP) and
global overall survival (OS) was carried out according to the
Kaplan–Meier method and compared by a two-tailored log-
rank test employing a statistical software S-Plus 6.0 Profes-
sional (Insightful Corporation ).17 Multivariate analysis was
carried out according to Cox regression model.18 Variables
that were considered for the models included age, perfor-
mance status, prior adjuvant treatment, site of metastatic
disease, and baseline carcinoembryonic antigen (CEA). All
statistical tests were two-sided.
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3.1. Patients population
Overall 287 caucasian patients with advanced CRC were as-
sessed. The main clinical characteristics of evaluated patients
according to basal bilirubin level are shown in Table 1. Briefly,
there were 208 evaluable patients (109 males and 99 females)
with a median age of 61 years (range 32–75), all treated with
FOLFIRI regimen every two weeks. One hundred twenty-eight
patients had a PS of 0, 73 patients had a PS of 1, and four pa-
tients had PS of 2. Three patients had not received PS evalua-
tion before the first chemotherapy cycle. Median basal
bilirubin level of the whole series was 0.79 mg/dl (range 0.1–
6.2 mg/dl). Fifty-one patients (24.5%) had a basal bilirubin
level 649 mg/dl, 108 patients (51.9%) had a bilirubin level be-
tween P0.5 and 60.99 mg/dl, 38 (18.2%)P 1 and 61.49 mg/
dl, and 11 patients (5.3%) had bilirubinP1.5 mg/dl. Forty-nine
patients had no disease in the liver, while 157 patients had
hepatic metastases. Among the latter group 118 patients
had liver lesions >10 cm. (H+ > 10), 39 patients had smaller li-
ver disease 610 cm (H+ 6 10). Median CEA level was 368 ng/dl
(range 0–6204 ng/dl). Basal bilirubin levels were not signifi-
cantly correlated to age, baseline PS, primary site of tumor,
baseline CEA, and haemoglobin levels. In addition, there were
no appreciable differences by prior pelvic irradiation, prior
adjuvant 5FU-based chemotherapy, number of organs in-
volved, and baseline WBC count (data not shown).
3.2. Survival analysis
Data concerning TTP are depicted in Fig. 1. Patients (n = 11)
with bilirubin higher >1.5 mg/dl had a median time-to-pro-
gression of 2.91 months as compared to 7.0, 7.19, and 8.11
months of patients with bilirubin >1.0–<1.5 mg/dl (n = 38),
P0.5–<0.99 mg/dl (n = 107) and <0.5 mg/dl (n = 51).
Fig. 2 shows the Kaplan–Meier distributions for OS by bili-
rubin category for the entire series.
OS correlated to basal bilirubin levels in a statistically sig-
nificant manner (p < 0.0001). The median survival of patients
(n = 11) with basal bilirubin levels >1.5 mg/dl was 4.93months,Table 1 – Patients clinical and demographical characteristics
Bilirubin <0.49 Bilirubin >0.5–<
No of patients 51 (24.5%) 108 (51.9%)
Median age 61.05 (32–74) 59.33 (35–74












CEA 256.58 (0.21–4508) 344.96 (0.00–495that of patients (n = 38) with bilirubin levels 1.0–1.49 mg/dl
was 12.43 months, while that of patients with bilirubin within
the normal limits was 13.87 months and 14.96 months,
respectively, for the group of patients (n = 107) with bilirubin
in the 0.49–1.0 mg/dl range and for the group (n = 51) with bil-
irubin <0.49 mg/dl (Table 2). In this series of patients median
survival is strongly correlated to basal bilirubin levels.
As shown in Table 2 multivariate Cox analysis (15) of sex,
age, PS, basal CEA levels, and presence of hepatic metastases
stratified according to basal bilirubin levels showed a statisti-
cally significant correlation only for the presence of hepatic
lesions (p = 0.019). Overall survival analysis of patients
according to liver metastasis burden is shown in Fig. 3 which
shows that survival is correlated to the presence and the size
of hepatic metastases (log-rank 0.0356).
3.3. Toxicity analysis
Toxicity grades of diarrhoea and neutropaenia recorded in the
series were plotted against baseline bilirubin levels. We eval-
uated rates and grade of toxicities, employing the worst de-
gree of toxicity of each patient. As shown in Fig. 4, both
neutropaenia and diarrhoea were correlated to baseline bili-
rubin levels in a statistically significant manner (p = 0.001).
By the first four cycles of chemotherapy, 75% of patients bili-
rubin >1.5 mg/dl required a toxicity-related dose-reduction as
compared to that with a lower initial bilirubin.
4. Discussion
We studied the influence of baseline serum bilirubin levels on
the activity and toxicity of chemotherapy in a cohort of 287
patients with aCRC, all treated in multicenter randomised tri-
als with the FOLFIRI regimen on a biweekly schedule. Data re-
ported in the present study confirm that basal bilirubin levels
of patients at entry are correlated to time-to-progression and
median overall survival (Figs. 1 and 2; p < 0.0001). Mild in-
crease in total baseline bilirubin levels (up to 1.5 mg/dl) did
not influence significantly the activity of CPT-11 in terms of
survival parameters, but further increase in bilirubin was
strongly correlated with reduced time-to-progression and0.99 Bilirubin >1–<1.49 Bilirubin >1.5
38 (18.2%) 11 (5.3%)
) 61.94 (32–75) 58.00 (43–74)
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Fig. 2 – Patients survival according to basal bilirubin levels.
Table 2 – Multivariate Cox analysis of sex, age, performance status, basal CEA levels and presence of hepatic metastases
stratified according to basal bilirubin levels
Coef Exp (coef) SE (coef) z p Exp (coef) Exp ()coef) Lower.95 Upper.95
Sex )0.0036575 0.996 0.2710 )0.0135 0.990 0.996 1.00 0.586 1.695
Age )0.0053868 0.995 0.0140 )0.3839 0.700 0.995 1.01 0.968 1.022
PS )0.0087000 0.991 0.2773 )0.0314 0.970 0.991 1.01 0.576 1.707
Mts )0.3464447 0.707 0.1473 )2.3522 0.019 0.707 1.41 0.530 0.944
CEA )0.0000282 1.000 0.0002 )0.1407 0.890 1.000 1.00 1.000 1.000
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is also correlated to the presence and the size of hepatic
metastases (Fig. 3; log-rank 0.0356).
Analysis of the relationship between baseline bilirubin lev-
els and CPT-11-induced diarrhoea and irinotecan-induced
neutropaenia showed a significant correlation for both side-ef-
fects (Fig. 4, p = 0.001). The importance of basal bilirubin levelsin predicting CPT-11-related toxicity is further strengthened by
the observation that dimension of liver metastases is the only
clinical parameter correlated with bilirubin levels (Table 2).
These observations are also meaningful if we consider the
increasing importance of CPT-11 in the management of aCRC,
and its use in combination with bevacizumab in the first-line
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Fig. 3 – Overall survival according to degree of liver involvement.
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Fig. 4 – Correlation between baseline bilirubin levels and degree of CPT-11-related toxicity.
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in medical literature. Recent studies19–21 have shown that
the toxicity experienced by patients with aCRC treated with
CPT-11-based regimens is correlated with basal bilirubin lev-
els and therefore with its metabolism and its genotype. More-
over, the presence of an altered hepatic metabolism may
reduce the antineoplastic activity of CTP-11. Innocenti
et al.22 have shown that UGT1A1 genotypes and total bilirubin
basal levels are strongly associated with an excess of severe
neutropaenia, suggesting that both parameters may be em-
ployed as predictive factors to identify patients potentially ex-
posed to severe toxicity if treated with CTP-11.
The data presented in our study are in accord with those
reported by Raymond et al.22 that showed that bilirubin levels
3 times higher than normal limits cause an exponential
reduction of CPT-11 clearance and an increase in neutropae-
nia rate which require a dose-reduction of chemotherapydrugs.23 Unfortunately, this study did not report correlation
between bilirubin and survival parameters. Since CPT-11
metabolism is tightly correlated to the UGT1A1 enzymatic
polymorphism24–26, responsible for metabolic variability,
analysis of genetic profile could be important in planning
the treatment of patients with CRC and to predict the
toxicology profile. Patients with omozygosis for the 28 allele
(UGTA1A1*28) display a higher risk of severe toxicity to CPT-
11.
In conclusion, our data strongly support previous reports
suggesting that in routine clinical practice patients with base-
line bilirubin levels above the normal limits should not be
treated with CPT-11-based regimen since the expected severe
toxicity could negatively by influence survival. This consider-
ation is further strengthened by the relatively shorter survival
of patients with abnormal bilirubin levels as compared to
those with normal values.
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